Faïza Khemissa - Concepedia

Author

Faïza Khemissa

Centre Hospitalier Universitaire de Tours

Also Known As

F Khemissa, F. Khemissa, Faiza Khemissa, Faïza Khemissa, Khemissa, Faiza

Publications

654

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Universitaire de Tours Assistance Publique – Hôpitaux de Paris Centre Georges François Leclerc Inserm Fédération Francophone de Cancérologie Digestive

About

Faïza Khemissa is an author at Centre Hospitalier Universitaire de Tours specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	410
2	Health Sciences	5	5	121
3	Hepatology	2	2	57
4	Gastroenterology	1	1	11
5	Geriatrics	1	1	49

Faïza Khemissa

Publications

593

Citations

H-Index

Page 1

	Year	Citations
Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physicians—Results of the NutriCancer2012 Study Emmanuel Gyan, Bruno Raynard, Jean‐Philippe Durand, Journal of Parenteral and Enteral Nutrition	2017	115
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02) Thomas Aparicio, Sandrine Lavau‐Denès, Jean–Marc Phelip, Annals of Oncology Elderly PatientsGastrointestinal OncologyMedicinePharmacologyClinical Trials	2015	104
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9) Thomas Aparicio, François Ghiringhelli, Valérie Boige, Journal of Clinical Oncology Prodige 9Surgical OncologyOncologyChemotherapy-free IntervalsMedian Tcd	2018	86
Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients Thomas Aparicio, D. Gargot, Laurent Teillet, European Journal of Cancer Geriatric OncologyOncologyGeriatric Factors AnalysesGastrointestinal OncologyGeriatrics	2016	49
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis Jean‐Frédéric Blanc, Faïza Khemissa, Jean–Pierre Bronowicki, Hepatology International HepatologyChild–pugh B CirrhosisHematologyClinical TrialsPediatrics	2021	47
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials Thomas Aparicio, Michel Ducreux, Roger Faroux, European Journal of Cancer ObesityFfcd TrialsGastrointestinal OncologyMedicineCancer Management	2018	39
Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001–02 trial). Results of a planned interim analysis Emmanuel Mitry, Jean–Marc Phelip, Franck Bonnetain, Critical Reviews in Oncology/Hematology Interim AnalysisOncologyElderly PatientsGastrointestinal OncologyPhase Iii Trial	2008	29
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial Jean‐Baptiste Bachet, Olivier Lucidarme, C.-B. Levaché, European Journal of Cancer Rectal Cancer PatientsSurgical OncologyGastrointestinal OncologyMedicineInduction Treatment	2018	25
Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer Alain R. Thierry, Brice Pastor, Ekaterina Pisareva, JAMA Network Open	2021	24
FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial. Marc Ychou, Michel Rivoire, Simon Thézenas, Journal of Clinical Oncology	2016	22

Page 1